This Group Learning program has been certified by the College of Family Physicians of Canada and Nova Scotia Chapter for up to 13.75 Mainpro+ credits.
To view the authorized presentations with your password, please click here have access to the presentation links.

Thursday September 23
10:00 am – 10:50 am (ET) Welcome from the Chair of CAGPO
CAGPO Scolarship Presentation
Dr. Tunji Fatoye & Dr. Andrew Knight
10:50 am – 10:55 am (ET) Break
10:55 am – 11:55 am (ET) Keynote - Exercise is Medicine
Dr. Melanie Keats
11:55 am – 12:25 pm (ET) Lunch / Virtual exhibition
12:25 pm – 1:25 pm (ET) Symposium: CAT-Recent Advances
Dr. Sudeep Shivakumar
1:25 pm – 1:30 pm (ET) Break
1:30 pm – 2:15 pm (ET) Spinal Cord Compression: The Neurosurgical Perspective
Dr. Sean Christie
2:15 pm – 2:20 pm (ET) Break
2:20 pm – 3:05 pm  (ET) Spinal Cord Compression and Other Radiation Oncology Issues
Dr. Maureen Nolan
3:05 pm – 3:35 pm (ET) Break / Virtual exhibition
3:35 pm – 4:35 pm (ET)
Metastatic Renal Cell Cancer and Other Genitourinary Cancer Updates
Dr. Lori Wood
6:30 pm – 8:00 pm (ET) CAGPO Business Meeting



Friday September 24
10:00 am – 10:30 am  (ET) Virtual exhibition
10:30 am – 11:15 am (ET) Metastatic Nonsmall Cell Lung Cancer
Dr. Stephanie Snow
11:15 am – 11:20 am (ET) Break
11:20 am – 12:05 pm (ET)
The Living Drug, A Tale of T-Cells
Dr. Mahmoud Elsawy
12:05 pm – 12:35 pm (ET) Lunch break / Virtual exhibition
12:35 pm – 1:35 pm (ET) Symposium: Metastatic Breast Cancer & CDK Inhibitors
Dr. Alwin Jeyakumar
1:35 pm – 1:40 pm (ET) Break
1:40 pm – 2:25 pm (ET) CINV: Treatment Advances
Dr. Stephanie Snow
2:25 pm – 2:30 pm (ET) Break
2:30 pm – 3:15 pm (ET) Targeted Therapies in Hematology Focusing on CLL
Dr. Sue Robinson
3:15 pm – 3:45 pm (ET) Break / Virtual exhibition
3:45 pm – 4:30 pm (ET) Management of Skin Toxicities Associated with EGFR Inhibitors
Dr. Nathan Lamond
TBC Entertainment Evening - TBC
Saturday, September 25
10:30 am – 11:00 am (ET) Virtual exhibition
11:00 am – 11:45 am (ET) Parp Inhibitors in Ovarian Cancer
Dr. Patti Power 
11:45 am – 11:50 am (ET) Break
11:50 am – 12:50 pm (ET) IVR and Tubes
Dr. Darren Knibutat
12:50 pm – 1:20 pm (ET) Lunch break / Virtual exhibition
1:20 pm – 2:20 pm (ET) Immuno-Oncology - Difficult Cases
Dr. Robyn MacFarlane
2:20 pm – 2:25 pm (ET) Break
2:25 pm – 3:10 pm (ET) Oligometastatic Disease & the Role of the Radiation Oncologist
Dr. Maureen Nolan
3:10 pm – 3:15 pm (ET) Break
3:15 pm – 4:15 pm (ET) ASCO-ESMO Update
Dr. Ron McCormick
4:15 pm – 4:30 pm (ET) Wrap up / The end


Learning Objectives

CAGPO 2021 General Conference Learning Objectives

At the completion of this educational opportunity, the learner will:
  • Comprehend recent advances in the treatment of hormone sensitive, Her2Neu negative metastatic breast cancer and metastatic non-small cell lung cancer;
  • Learn about CAGPO’s scholarship opportunities;
  • Acquire a working knowledge of advances in treatment of cancer associated thrombosis;
  • Be able to evaluate the data concerning major advances presented at ASCO and ESMO in 2021;
  • Be able to implement improved toxicity management regarding immune-oncology drugs;
  • Be able to evaluate the role of CAR-T cells in hematological malignancies;
  • Be able to apply knowledge acquired regarding treatment advances in chemotherapy induced nausea and vomiting;
  • Comprehend the role of PARP inhibitors in metastatic ovarian cancer;
  • Comprehend the benefits of advising exercise to the oncology patient;
  • Understand the role of the interventional radiologist in palliative symptom management;
  • Understand the role of neurosurgical intervention  and radiation in spinal cord compressions;
  • Be able to apply knowledge acquired regarding skin toxicity management due to EGFR inhibitors;
  • Be able to evaluate data regarding major advances in genitourinary cancers;
  • Be able to apply knowledge acquired regarding the treatment of CLL,  and 
  • Comprehend advances in radiation treatment regarding spinal cord compression, hippocampal sparing, radiation necrosis as well as the role of radiation in the treatment of oligometastatic disease.